Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \& Co. KG.

Who May Be Eligible (Plain English)

Who May Qualify: - Prescription of Rinvoq™ from January 1, 2024; - 18 years of age or older at the time of recruitment; and - Expressed consent to participate in the study. Who Should NOT Join This Trial: - They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone; - They are participating in a phase I, II, or III clinical trial; - They have a life expectancy of less than 1 month; or - They do not have a valid telephone contact. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Prescription of Rinvoq™ from January 1, 2024; * 18 years of age or older at the time of recruitment; and * Expressed consent to participate in the study. Exclusion Criteria: * They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone; * They are participating in a phase I, II, or III clinical trial; * They have a life expectancy of less than 1 month; or * They do not have a valid telephone contact.

Treatments Being Tested

DRUG

Upadacitinib

Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).

Locations (3)

Unidade Local de Saúde de Santo António, E.P.E.
Porto, Portugal
Unidade Local de Saúde de São João, E.P.E.
Porto, Portugal
Unidade Local de Saúde de Gaia/Espinho, E.P.E.
Porto, Portugal